SOLICITATION NOTICE
A -- Broad Agency Announcement, Science and Technology Platforms Applied to Medical Countermeasure Development (Innovations) for BARDA
- Notice Date
- 7/16/2013
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, Office of the Secretary, Acquisitions Management, Contracts, & Grants (AMCG), Office of the Assistant Secretary for Preparedness & Response (ASPR), Department of Health and Human Services, 330 Independence Ave. SW, G640, Washington, District of Columbia, 20201, United States
- ZIP Code
- 20201
- Solicitation Number
- BAA-13-100-SOL-00014
- Point of Contact
- Elizabeth Steiner, Phone: 202-205-8926, Nathaniel Cohen, Phone: 202-205-8968
- E-Mail Address
-
Elizabeth.Steiner@hhs.gov, Nathaniel.Cohen@hhs.gov
(Elizabeth.Steiner@hhs.gov, Nathaniel.Cohen@hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- BARDA encourages the advanced research, development and acquisition of medical countermeasures such as vaccines, therapeutics, and diagnostics, as well as innovative approaches to support the preparedness mission and priorities of the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) articulated in the 2012 PHEMCE Implementation Plan. The Implementation Plan is located on the ASPR website: https://www.medicalcountermeasures.gov/media/13962/2012-phemce-implementation-plan.pdf The Pandemic and All Hazard Preparedness Act Pub. L. No. 109-417, 42 U.S.C. § 241 et seq. (PAHPA; http://www.gpo.gov/fdsys/pkg/PLAW-109publ417/pdf/PLAW-109publ417.pdf) and The Pandemic and All Hazard Preparedness Reauthorization Act Pub. L. No. 113-5, (PAHPRA: http://www.gpo.gov/fdsys/pkg/PLAW-113publ5/pdf/PLAW-113publ5.pdf) authorizes BARDA to (i) conduct ongoing searches for, and support calls for, potential qualified countermeasures and qualified pandemic or epidemic products; (ii) direct and coordinate the countermeasure and product advanced research and development activities of the Department of Health and Human Services; (iii) establish strategic initiatives to accelerate countermeasure and product advanced research and development (which may include advanced research and development for purposes of fulfilling requirements under the Federal Food, Drug, and Cosmetic Act or section 351 of this Act) and innovation in such areas as the Secretary may identify as priority unmet need areas; and (iv) award contracts, grants, cooperative agreements, and enter into other transactions, for countermeasure and product advanced research and development. A key to success in this broad, challenging mission is identifying and advancing innovative technologies that will provide capabilities for novel countermeasures with improved performance, as well as for their expedited development, manufacturing, and use. Through its Innovative Technologies program, BARDA has invested in basic and applied technology platforms that have enabled the development of new medical countermeasures and provided tools with the potential to be applied to other existing or future pathogens and threats. The purpose of this announcement is to identify an Area of Interest (AOI) in which BARDA is currently seeking products, technologies, or capabilities that will advance effective medical countermeasure emergency response. BARDA is specifically interested in supporting the advancement of tools that can demonstrate an impact on the design, development, or use of a medical countermeasure for use in a public health emergency, but additional information that indicates the potential to be applied more broadly is welcomed. Technology platforms within this Strategic Science and Technology (SST) AOI may be applicable to vaccines, therapeutics, or diagnostics across the PHEMCE threat space. SST Area of Interest #1: Technologies that facilitate administration of medical countermeasures during a public health emergency 1.1 Technologies, such as jet injectors or autoinjectors, that may allow vaccines or drugs to be delivered by parenteral administration with limited access to trained medical personnel resources 1.2 Technologies, such as oral or transdermal delivery, that allow non-parenteral administration by the user and may deliver the countermeasure over a longer time interval The Government intends to conduct a full and open competition for this requirement in the form of a BAA. This synopsis is not a BAA; a BAA itself is anticipated to be posted on or about July 31, 2013. The Government expects to make 1 or more awards, subject to the availability of funds. The open period of the BAA will be specified in the BAA itself. Contact Information: Comments to this announcement, referencing synopsis BAA-13-100-SOL-00014 may be submitted to the following email address: SST-BAA@hhs.gov Contracting Office Address: Department of Health & Human Services (DHHS) Office of the Assistant Secretary for Preparedness & Response (ASPR) Acquisition Management Contracts & Grants (AMCG) 330 Independence Ave., S.W., Room G-640 Washington, D.C. 20201
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/OOS/OASPHEP/BAA-13-100-SOL-00014/listing.html)
- Record
- SN03118037-W 20130718/130716235509-5b619cd6eb2400b2ff23979f3b67a440 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |